Quantum Computing Inc. (QCi) (Nasdaq: QUBT) has announced a collaboration with the Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI) to support computational biomedicine research. QCi will provide Sanders TDI with cloud-based access to its Dirac-3 Entropy Quantum Computing systems, which operate at room temperature and low power, to assist in solving complex optimization problems in drug discovery and biomolecular modeling.
Sanders TDI, a non-profit drug discovery institute comprising Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine, focuses on advancing preclinical studies to block disease initiation and progression. The collaboration will explore quantum-enabled applications in computational chemistry, aiming to identify promising use cases for QCi’s Dirac systems in biomedical research.
Dr. William McGann, CEO of QCi, emphasized the partnership’s alignment with the company’s mission to make quantum computing accessible and affordable, highlighting its potential to deliver actionable insights in real-world applications.
For more information, visit QCi’s press release here.
January 16, 2025
Leave A Comment